Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Varicella Clinical Trial

Official title:

A Randomized, Blind, Controlled Clinical Trial to Evaluate Safety and Immunogenicity of Live Attenuated Varicella Vaccine After a Two-dose Vaccination Course in Healthy Population Aged ≥13 Years Old

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05015686
• Other study ID #: PRO-VZV-4002
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: September 30, 2021
• Est. completion date: September 20, 2026

Study information

• Verified date: March 2024
• Source: Sinovac (Dalian) Vaccine Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses vaccination of investigational vaccine with 0,28 day, 0,42 day and 0,56 day immunization schedule in population aged ≥13 years old.

Description:

This study is a randomized, blind, controlled phase # clinical trial in population aged ≥13 years old. The experimental vaccine will be manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.A total of 2400 subjects aged 13 years and older will be enrolled with1200 subjects in 13 ~ 17 years old group and1200 subjects in 18 years and older group.960 subjects in each age group will be randomly divided into experimental group and control group according to 1:1 ratio,and subjects will receive two doses of vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days. An additional 240 subjects in each age group will be randomly divided into experimental group and control group according to 2:1 ratio to receive two doses of the experimental vaccine or placebo with the immunization course of 0, 70 days.In addition,400 subjects including 320 people of experimental group in different immunization course according to the difference of age and 80 people of placebo group according to the difference of age will be selected to collect blood about 3ml each time to evaluate immunity persistence of live attenuated varicella vaccines at 3 and 5 years after the whole immunization.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 2400
• Est. completion date: September 20, 2026
• Est. primary completion date: February 9, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Healthy population aged 13 years and above;

• Proven legal identity;

• The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 13-17 years, both subjects and guardians need to sign the informed consent form);

Exclusion Criteria:

• History of chickenpox or shingles;

• Axillary temperature >37.0°C;

• Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 6 months;

• History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;

• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;

• Autoimmune disease or immunodeficiency / immunosuppression;

• Severe chronic diseases, severe cardiovascular diseases,hypertension(adult field measurement: SBP =140mmHg or diastolic blood pressure =90mmHg)and diabetes that cannot be controlled by drugs, liver or kidney diseases;

• Family history of psychosis,severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;

• Thyroid disease or history of thyroidectomy, asplenia, functional asplenia,asplenia or splenectomy resulting from any condition;

• Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;

• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;

• History of alcohol or drug abuse;

• Receipt of blood products within in the past 3 months;

• Participating in other drug/vaccine clinical trial;

• Receipt of attenuated live vaccines in the past 28 days;

• Receipt of inactivated or subunit vaccines in the past 7 days;

• Onset of various acute or chronic diseases within 7 days prior to the study;

• According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Related Conditions & MeSH terms

• Chickenpox
• Herpes Zoster
• Varicella

Intervention

Biological:
• Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
• Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
• Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
• Placebo
Sodium chloride and distilled water

Locations

Country	Name	City	State
China	Yucheng Center for Disease Control and Prevention	Shangqiu	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroconversion rate of the antibody	The seroconversion rate of the antibody 28 days among all subjects after the second vaccination.	Day 28 after the whole schedule
Primary	GMT of the antibody	The GMT of the antibody 28 days among all subjects after the second vaccination.	Day 28 after the whole schedule
Secondary	GMI of the antibody	GMI of the antibody 28 days among all subjects after the second vaccination.	Day 28 after the whole schedule
Secondary	Seroconversion rate, positive rate, GMT and GMI of the antibody	Seroconversion rate, positive rate, GMT and GMI of the antibody among all subjects on day 28,day 42 and day 56 after the first vaccination.	Day 28,Day 42 and day 56 after the first vaccination
Secondary	Incidence of adverse reactions within 0~28 days after each dose	Incidence of adverse reactions within 0~28 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days.	Within 0~28 days after each dose
Secondary	Incidence of adverse reactions within 0~14 days after each dose vaccination	Incidence of adverse reactions within 0~14 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days	Within 0~14 days after each dose
Secondary	Incidence of grade 3 and above adverse reactions	Incidence of grade 3 and above adverse reactions within 0~28 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days.	within 0~28 days after each dose
Secondary	Incidence of serious adverse events	Incidence of serious adverse events from vaccination to 6 months after the second vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days	From vaccination to 6 months after the second vaccination